Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...

Recent & Breaking News (NYSEAM:LCTX)

BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World Stem Cell Summit

Business Wire December 11, 2015

BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation

Business Wire December 11, 2015

BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference

Business Wire December 4, 2015

LifeMap Solutions Launches COPD Navigator App for Consumers and Commercial Partners

Business Wire December 3, 2015

BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer

Business Wire November 18, 2015

BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments

Business Wire November 9, 2015

BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market

Business Wire November 6, 2015

Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.

Business Wire October 19, 2015

BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution

Business Wire October 7, 2015

BioTime, Inc. Agrees to Sell $5.1 Million of Equity

Business Wire October 2, 2015

BioTime Announces the Closing of a $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered

Business Wire October 1, 2015

Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements

Business Wire September 30, 2015

Mount Sinai and LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact

Business Wire September 29, 2015

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration

Business Wire September 28, 2015

BioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares

Business Wire September 25, 2015

BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond to its Board of Directors

Business Wire September 14, 2015

BioTime, Inc. Agrees to Sell $8.58 Million of Common Shares

Business Wire September 14, 2015

BioTime Announces Dual Listing on the Tel Aviv Stock Exchange

Business Wire September 4, 2015

BioTime Chief Executive Officer Dr. Michael D. West to be Keynote Speaker at Stem Cells & Regenerative Medicine Congress 2015

Business Wire September 1, 2015

BioTime Subsidiary Asterias Therapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury

Business Wire August 31, 2015